The board of directors of ImmuneOnco Biopharmaceuticals (Shanghai) Inc. announced the following changes to the Board and management of the Company: Ms. Song Ziyi has tendered her resignation as an executive Director and the chief financial officer of the Company, with effect from March 2, 2024, in order to devote more time to her other business commitments. Following the resignation of Ms. Song, she has also ceased to be an authorized representative of the Company (the "Authorized Representative") under Rule 3.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. The Board announced that, Dr. Tian Wenzhi, the chairman of the Board, the chief executive officer, the chief scientific officer and an executive Director of the Company, has been appointed as an Authorized Representative with effect from March 2, 2024 to fill the vacancy following Ms. Song's cessation to act in the same capacity.